Literature DB >> 29927359

Is the matched extreme case-control design more powerful than the nested case-control design?

N C Støer1,2, A Salim3,4, K Bokenberger1, I Karlsson1, M Reilly1.   

Abstract

For time-to-event data, the study sample is commonly selected using the nested case-control design in which controls are selected at the event time of each case. An alternative sampling strategy is to sample all controls at the same (pre-specified) time, which can either be at the last event time or further out in time. Such controls are the long-term survivors and may therefore constitute a more 'extreme' comparison group and be more informative than controls from the nested case-control design. We investigate this potential information gain by comparing the power of various 'extreme' case-control designs with that of the nested case-control design using simulation studies. We derive an expression for the theoretical average information in a nested and extreme case-control pair for the situation of a single binary exposure. Comparisons reveal that the efficiency of the extreme case-control design increases when the controls are sampled further out in time. In an application to a study of dementia, we identified Apolipoprotein E as a risk factor using a 1:1 extreme case-control design, which provided a hazard ratio estimate with a smaller standard error than that of a 2:1 nested case-control design.

Entities:  

Keywords:  Extreme case–control; logistic regression; matched design; power; weighted likelihood

Year:  2018        PMID: 29927359     DOI: 10.1177/0962280218778624

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  2 in total

1.  Sampling strategies to evaluate the prognostic value of a new biomarker on a time-to-event end-point.

Authors:  Francesca Graziano; Maria Grazia Valsecchi; Paola Rebora
Journal:  BMC Med Res Methodol       Date:  2021-04-30       Impact factor: 4.615

2.  Which patients to sample in clinical cohort studies when the number of events is high and measurement of additional markers is constrained by limited resources.

Authors:  Dominic Edelmann; Kristin Ohneberg; Natalia Becker; Axel Benner; Martin Schumacher
Journal:  Cancer Med       Date:  2020-08-19       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.